COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome (ProPit)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00640276
Recruitment Status : Completed
First Posted : March 21, 2008
Last Update Posted : March 30, 2012
Information provided by (Responsible Party):
JW Pharmaceutical

Brief Summary:
We will identify the influence of long-term treatment of Pitavastatin compared to non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic syndrome component score. And we will additionally observe the changes of CVD risk factors like lipid profile, abdominal fat, insulin resistance and so on.

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Metabolic Syndrome Drug: pitavastatin Behavioral: Lifestyle Modification Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 187 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome
Study Start Date : April 2008
Actual Primary Completion Date : February 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: T
Lifestyle modification + active drug(Pitavastatin)
Drug: pitavastatin
Pitavastatin 2mg daily once
Other Name: Livaro

Lifestyle Modification
Behavioral: Lifestyle Modification
conducting mainly exercises and diet

Primary Outcome Measures :
  1. A change of metabolic syndrome risk component [ Time Frame: 48week ]

Secondary Outcome Measures :
  1. Changes of cardiometabolic profiles : lipid profiles, hs-CRP, adiponectin, HMW adiponectin [ Time Frame: 48week ]
  2. Changes of abdominal visceral fat [ Time Frame: 48week ]
  3. Changes of insulin resistance : OGTT(75g), HOMA [ Time Frame: 48week ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients aged between 18 and 75
  • Patients with LDL ≥ 100mg/dL
  • Patients with metabolic syndrome

    1. IFG: Fasting glucose ≥ 100mg/dL
    2. Abdominal Obesity: Waist circumference: men≥90cm,women≥85cm
    3. 1 or more of the following

      1. Triglyceride ≥ 150mg/dL
      2. HDL-C: men < 40mg/dL, women < 50mg/dL
      3. Blood pressure: SBP ≥ 130mmHg or DBP ≥ 85mmHg or subject receiving anti-hypertensive treatment

Exclusion Criteria:

  • uncontrolled hypertension (DBP ≥ 95mmHg)
  • taking diabetic drugs or with HbA1c > 8%
  • LDL ≥ 190mg/dL or Triglyceride ≥ 400mg/dL
  • coronary heart disease or other diseases caused by artherosclerosis
  • malignancy within 6 months
  • Serum creatinine ≥ 2.0mg/dL
  • ALT or AST ≥ ULN*2.5
  • CPK ≥ ULN*2
  • hypothyroidism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00640276

Layout table for location information
Korea, Republic of
Seoul National University Bundang Hospital
Bundang-gu, Gyeonggi-do, Korea, Republic of, 463-707
Hanyang Univ. Guri Hospital
Guri-si, Gyeonggi-do, Korea, Republic of, 471-701
Sponsors and Collaborators
JW Pharmaceutical
Layout table for investigator information
Study Chair: Chang Beom Lee Hanyang Univ. Guri Hospital
Study Chair: Hak Chul Jang Seoul National University Bundang Hospital
Layout table for additonal information
Responsible Party: JW Pharmaceutical Identifier: NCT00640276    
Other Study ID Numbers: CWP_PTV_706
First Posted: March 21, 2008    Key Record Dates
Last Update Posted: March 30, 2012
Last Verified: March 2012
Keywords provided by JW Pharmaceutical:
metabolic syndrome
metabolic syndrome risk score
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Lipid Metabolism Disorders
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents